EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Pemafibrate Increases Circulating Angiopoietin-like Proteins 3 and 4 Without Promoting Pro-Atherogenic Changes in LDL and HDL Subspecies: A Post-Hoc Analysis of the PRESTIGE Study

Tsutomu Hirano, Toshiyuki Hayashi, Hiroe Sugita, Atsuko Tamasawa, Makoto Ohara, Michishige Terasaki, Yasuki Ito, Sho-Ichi Yamagishi, Yusaku Mori

Journal of Atherosclerosis and Thrombosis · 2026

DOI: 10.5551/jat.65941 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Atherosclerosis and Thrombosis, 2026. Verfasst von Tsutomu Hirano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa Medical University, Shinagawa. Hauptthemen laut MEDLINE: Angiopoietin-Like Protein 4, Butyrates, Angiopoietin-like Proteins, Benzoxazoles. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiopoietin-Like Protein 4ButyratesAngiopoietin-like ProteinsBenzoxazolesDiabetes Mellitus, Type 2Cholesterol, LDLAtherosclerosisHypertriglyceridemiaCholesterol, HDLHumansMaleFemaleMiddle AgedAngiopoietin-Like Protein 3AgedHydroxymethylglutaryl-CoA Reductase InhibitorsBiomarkers

Stichwörter der Autor:innen

Angiopoietin-like proteinsLipoprotein subspeciesPemafibrateStatins

Substanzen

Angiopoietin-Like Protein 4(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidAngiopoietin-Like Protein 3ANGPTL4 protein, humanButyratesAngiopoietin-like ProteinsBenzoxazolesANGPTL3 protein, humanCholesterol, LDLHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa Medical University, Shinagawa.
  • Diabetes Center, Ebina General Hospital.
  • Yurakubashi Clinic.
  • Asoka Hospital.
  • Clinical Diagnostics Department, Denka Co., Ltd.
  • Division of Diabetes, Metabolism, and Endocrinology, Anti-glycation Research Section, Department of Medicine.

Zitieren

APA

Hirano, T., Hayashi, T., Sugita, H., Tamasawa, A., Ohara, M., Terasaki, M., Ito, Y., Yamagishi, S. I., & Mori, Y. (2026). Pemafibrate Increases Circulating Angiopoietin-like Proteins 3 and 4 Without Promoting Pro-Atherogenic Changes in LDL and HDL Subspecies: A Post-Hoc Analysis of the PRESTIGE Study. Journal of Atherosclerosis and Thrombosis. https://doi.org/10.5551/jat.65941

Vancouver

Hirano T, Hayashi T, Sugita H, Tamasawa A, Ohara M, Terasaki M, et al. Pemafibrate Increases Circulating Angiopoietin-like Proteins 3 and 4 Without Promoting Pro-Atherogenic Changes in LDL and HDL Subspecies: A Post-Hoc Analysis of the PRESTIGE Study. Journal of Atherosclerosis and Thrombosis. 2026. doi:10.5551/jat.65941

BibTeX
@article{Hirano2026,
  author = {Hirano, Tsutomu and Hayashi, Toshiyuki and Sugita, Hiroe and Tamasawa, Atsuko and Ohara, Makoto and Terasaki, Michishige and Ito, Yasuki and Yamagishi, Sho-Ichi and Mori, Yusaku},
  title = {Pemafibrate Increases Circulating Angiopoietin-like Proteins 3 and 4 Without Promoting Pro-Atherogenic Changes in LDL and HDL Subspecies: A Post-Hoc Analysis of the PRESTIGE Study},
  journal = {Journal of Atherosclerosis and Thrombosis},
  year = {2026},
  doi = {10.5551/jat.65941}
}
Kostenlos starten →